Wehrli Marc, Schneider Christoph, Cortinas-Elizondo Fabiola, Verschoor Daniëlle, Frias Boligan Kayluz, Adams Olivia Joan, Hlushchuk Ruslan, Engelmann Christine, Daudel Fritz, Villiger Peter M, Seibold Frank, Yawalkar Nikhil, Vonarburg Cédric, Miescher Sylvia, Lötscher Marius, Kaufmann Thomas, Münz Christian, Mueller Christoph, Djonov Valentin, Simon Hans-Uwe, von Gunten Stephan
Institute of Pharmacology, University of Bern, 3010 Bern, Switzerland.
Institute of Anatomy, University of Bern, 3012 Bern, Switzerland.
J Immunol. 2020 Nov 15;205(10):2640-2648. doi: 10.4049/jimmunol.1900883. Epub 2020 Oct 2.
IVIG preparations consisting of pooled IgG are increasingly used for the treatment of autoimmune diseases. IVIG is known to regulate the viability of immune cells, including neutrophils. We report that plasma-derived IgA efficiently triggers death of neutrophils primed by cytokines or TLR agonists. IgA-mediated programmed neutrophil death was PI3K-, p38 MAPK-, and JNK-dependent and evoked anti-inflammatory cytokines in macrophage cocultures. Neutrophils from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were susceptible to both IgA- and IVIG-mediated death. In contrast to IVIG, IgA did not promote cell death of quiescent neutrophils. Our findings suggest that plasma-derived IgA might provide a therapeutic option for the treatment of neutrophil-associated inflammatory disorders.
由混合IgG组成的静脉注射免疫球蛋白(IVIG)制剂越来越多地用于治疗自身免疫性疾病。已知IVIG可调节免疫细胞的活力,包括中性粒细胞。我们报告称,血浆来源的IgA能有效触发由细胞因子或Toll样受体(TLR)激动剂引发的中性粒细胞死亡。IgA介导的程序性中性粒细胞死亡依赖于磷脂酰肌醇-3激酶(PI3K)、p38丝裂原活化蛋白激酶(MAPK)和c-Jun氨基末端激酶(JNK),并在巨噬细胞共培养中诱发抗炎细胞因子。急性克罗恩病、类风湿性关节炎或脓毒症患者的中性粒细胞对IgA和IVIG介导的死亡均敏感。与IVIG不同,IgA不会促进静止中性粒细胞的细胞死亡。我们的研究结果表明,血浆来源的IgA可能为治疗与中性粒细胞相关的炎症性疾病提供一种治疗选择。